The combination of FXR agonist plus EZH2 inhibitor exerts synergistic tumor inhibition in CRC both in vitro and in vivo by dramatically accelerating FXR nuclear location and cooperatively upregulating CDX2 expression. Here, CDX2 is linked to colorectal carcinoma.